BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
August 10, 2021 07:00 ET
|
BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...